- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05798507
Identification of Treatment Concentrations of Defactinib or VS-6766 for the Treatment of Patients With Glioblastoma
A Single-Dose Study of Orally Administrated Defactinib or VS-6766 in Patients With Glioblastoma
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
PRIMARY OBJECTIVES:
I. Estimate (or characterize) the concentration of defactinib or avutometinib (VS-6766) that accumulates in the glioblastoma (GBM) and brain around tumor.
II. Assess the safety of the administration of a single oral dose of defactinib or VS-6766 in patients with glioblastoma.
III. Assess the inhibition of Pyk2/FAK or MEK, Erk signaling in tumor and brain around tumor.
IV. Assess the pharmacodynamics of defactinib or VS-6766 in patients with glioblastoma.
OUTLINE: This is a dose-escalation study of defactinib and avutometinib. Patients are assigned to 1 of 2 arms.
ARM I: Patients receive 1 dose of defactinib orally (PO) while on study, prior to planned tumor resection.
ARM II: Patients receive 1 dose of avutometinib PO while on study, prior to planned tumor resection.
Patients undergo blood collection and donate resected tumor tissue while on study.
Study Type
Enrollment (Estimated)
Phase
- Early Phase 1
Contacts and Locations
Study Contact
- Name: Jeffrey J. Olson, MD
- Phone Number: 404-778-5770
- Email: jolson@emory.edu
Study Locations
-
-
Georgia
-
Atlanta, Georgia, United States, 30322
- Recruiting
- Emory University Hospital/Winship Cancer Institute
-
Contact:
- Agnes Harutyunyan
- Phone Number: 404-778-7215
- Email: aharuty@emory.edu
-
Principal Investigator:
- Jeffrey J. Olson, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- New or recurrent glioblastoma diagnosed by neuroimaging techniques for which surgical resection is indicated
- Age older than 21 years
- An Eastern Cooperative Group (ECOG) performance status =< 1
- Hemoglobin (Hb) >= 9.0 g/dL. If a red blood cell transfusion has been administered the Hb must remain stable and >= 9.0 g/dL for at least 1 week prior to first dose of study therapy.
- Platelets >= 100,000/mm^3
- Absolute neutrophil count (ANC) >= 1500/mm^3
- Total bilirubin =< 1.5 × upper limit of normal (ULN) per the institution; patients with Gilbert syndrome may enroll if total bilirubin < 3.0 mg/dL (51 umole/L)
- Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 × ULN (or < 5x ULN in patients with liver metastases)
- Creatinine clearance rate of >= 50 mL/min as calculated by the Cockcroft-Gault formula or serum creatinine of =< 1.5 x ULN
- Albumin >= 3.0 g/dL (451 umole/L)
- Creatine phosphokinase (CPK) =< 2.5 x ULN
- Left ventricular ejection fraction >= 50% by echocardiography (ECHO) or multiple-gated acquisition (MUGA) scan
- Baseline QTc interval < 460 ms for women and =< 450 ms for men (average of triplicate readings) (Common Terminology Criteria for Adverse Events [CTCAE] Grade 1) using Fredericia's QT correction formula. NOTE: This criterion does not apply to subjects with a right or left bundle branch block
- Adequate recovery from toxicities related to prior treatments to at least Grade 1 by CTCAE v 5.0. Exceptions include alopecia and peripheral neuropathy grade =< 2
- Male and female patients with reproductive potential agree to use highly effective method of contraceptive (per Clinical Trial Facilitation Group [CFTG] recommendations) during the trial and for 3 months following the last dose of VS-6766 for male patients, and 1 month following the last dose of VS-6766 for female patients.
Exclusion Criteria:
- Clinically significant gastrointestinal abnormalities, requirement for systemic anticoagulation or potent CYP 2C8 inhibitors, and history of clinically significant cardiac or pulmonary disorders
- Minors will be excluded from the investigation. Glioblastoma is the major form of brain cancer in people over 50 years old. Pediatric cases of glioblastoma are relatively rare. Besides this, there are crucial molecular differences between adult and pediatric gliomas. Our preliminary data for proposed investigation were obtained on GBM specimens and cultures developed from GBM tissues donated by adult subjects. Results of investigation of adult glioma tissue cannot simply be extrapolated to children. Therefore, our primary research focus is the investigation of GBM in adults. If appropriate, a separate, age-specific study in children will be performed
- Pregnant women will be excluded from the study as altered hormonal and immunological status can affect the study results
- Prisoners will be excluded from the study
- Systemic anti-cancer therapy within 4 weeks of the first dose of study therapy
- History of prior malignancy, with the exception of curatively treated malignancies or malignancies with very low potential for recurrence or progression
- Major surgery within 4 weeks (excluding placement of vascular access), minor surgery within 2 weeks, or palliative radiotherapy within 1 week of the first dose of VS-6766
Exposure to medications (with or without prescription), supplements, herbal remedies, or foods with potential for drug-drug interactions with VS-6766 within 14 days prior to the first dose of VS-6766 and during the course of therapy, including:
- VS-6766: strong CYP3A4, inhibitors or inducers, due to potential drug-drug interactions with VS-6766 and/or defactinib
- Defactinib: strong CYP3A4, CYP2C9, and P-glycoprotein (P-gp) inhibitors or inducers, due to potential drug-drug interactions with VS-6766 and/or defactinib
- Known hepatitis B, hepatitis C or human immunodeficiency virus (HIV) infection that is active and/or requires therapy
- Active skin disorder that has required systemic therapy within the past 1 year
- History of rhabdomyolysis
Concurrent ocular disorders:
- Patients with history of glaucoma, history of retinal vein occlusion (RVO), predisposing factors for RVO, including uncontrolled hypertension, uncontrolled diabetes
- Patients with history of retinal pathology or evidence of visible retinal pathology that is considered a risk factor for RVO, intraocular pressure > 21 mm Hg as measured by tonometry, or other significant ocular pathology, such as anatomical abnormalities that increase the risk for RVO
- Patients with a history of corneal erosion (instability of corneal epithelium), corneal degeneration, active or recurrent keratitis, and other forms of serious ocular surface inflammatory conditions
- Concurrent congestive heart failure, prior history of class III/ IV cardiac disease (New York Heart Association [NYHA]), myocardial infarction within the last 6 months, unstable arrhythmias, unstable angina, or severe obstructive pulmonary disease
- Patients with the inability to swallow oral medications or impaired gastrointestinal absorption due to gastrectomy or active inflammatory bowel disease
- Patients with a history of hypersensitivity to any of the inactive ingredients (hydroxypropylmethylcellulose, mannitol, magnesium stearate) of the investigational product
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Arm I (Defactinib)
Patients receive 1 dose of defactinib PO while on study, prior to planned tumor resection.
Patients undergo blood collection and donate resected tumor tissue while on study.
|
Given PO
Undergo blood and tissue sample collection
Other Names:
|
Experimental: Arm II (Avutometinib)
Patients receive 1 dose of avutometinib PO while on study, prior to planned tumor resection.
Patients undergo blood collection and donate resected tumor tissue while on study.
|
Undergo blood and tissue sample collection
Other Names:
Given PO
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Concentration of defactinib that accumulates in the glioblastoma (GBM) and brain around tumor
Time Frame: At time of surgery
|
Defactinib concentration will be measured in a sample of the glioblastoma, brain around the glioblastoma, and in a serum sample from each subject receiving Defactinib.
Descriptive statistics, such as mean and standard deviation, will be generated with these results.
Concentration will be compared between dose levels within study drug using two-sample t-tests or non-parametric equivalents such as Mann Whitney U tests.
|
At time of surgery
|
Concentration of avutometinib (VS-6766) that accumulates in the GBM and brain around tumor
Time Frame: At time of surgery
|
VS-6766 concentration will be measured in a sample of the glioblastoma, brain around the glioblastoma, and in a serum sample from each subject receiving VS-6766.
Descriptive statistics, such as mean and standard deviation, will be generated with these results.
Concentration will be compared between dose levels within study drug using two-sample t-tests or non-parametric equivalents such as Mann Whitney U tests.
|
At time of surgery
|
Incidence of adverse events associated with defactinib
Time Frame: Up to 2 weeks post surgery
|
Will be assessed by quantification of the recognized side effects of this agent including fatigue, nausea, diarrhea, vomiting, hyperbilirubinemia, decreased appetite, peripheral edema, dizziness, and headache and by monitoring for new or undescribed adverse events.
Summary statistics will include frequencies and percentages of adverse events.
|
Up to 2 weeks post surgery
|
Incidence of adverse events associated with VS-6766
Time Frame: Up to 2 weeks post surgery
|
Will be assessed by quantification of the recognized side effects of this agent including rash, creatine phosphokinase elevation, visual disturbances, hypoalbuminemia, and fatigue and by monitoring for new or undescribed adverse events.
Summary statistics will include frequencies and percentages of adverse events.
|
Up to 2 weeks post surgery
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pyk2 and FAK phosphorylation in tumor, brain around tumor, and serum
Time Frame: At time of surgery
|
These results will be summarized with descriptive statistics.
These results will be compared to current and historical control samples of glioblastoma (collected in our previous human GBM specimens' studies) and analyzed in parallel with study subject samples and run on one western blot membrane to reduce technique variation.
The mean phosphorylation will be compared between groups using two-sample t-test or non-parametric equivalents such as Mann Whitney U tests.
Dose levels will be compared to a historical control, both alone and combined.
|
At time of surgery
|
MEK and Erk in tumor, brain around tumor, and serum
Time Frame: At time of surgery
|
These results will be summarized with descriptive statistics.
These results will be compared to current and historical control samples of glioblastoma (collected in our previous human GBM specimens' studies) and analyzed in parallel with study subject samples and run on one western blot membrane to reduce technique variation.
Phosphorylation will be compared between dose levels within study drug using two-sample t-tests or non-parametric equivalents such as Mann Whitney U tests.
|
At time of surgery
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Jeffrey J Olson, MD, Emory University Hospital/Winship Cancer Institute
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- STUDY00004876 (Other Identifier: Emory University Hospital/Winship Cancer Institute)
- P30CA138292 (U.S. NIH Grant/Contract)
- NCI-2023-00602 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
- WINSHIP5751-22 (Other Identifier: Emory University Hospital/Winship Cancer Institute)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Glioblastoma
-
Celldex TherapeuticsCompletedGlioblastoma | Gliosarcoma | Recurrent Glioblastoma | Small Cell Glioblastoma | Giant Cell Glioblastoma | Glioblastoma With Oligodendroglial Component | Relapsed GlioblastomaUnited States
-
Juan M Garcia-GomezHospital Universitario 12 de Octubre; Hospital Clínico Universitario de ValenciaRecruitingGlioblastoma | Glioblastoma Multiforme | High Grade Glioma | Astrocytoma, Grade IV | Glioblastoma, IDH-mutant | Glioblastoma, IDH-wildtype | Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype | Glioblastoma IDH (Isocitrate Dehydrogenase) MutantSpain
-
Jasper GerritsenMassachusetts General Hospital; Universitaire Ziekenhuizen KU Leuven; University... and other collaboratorsRecruitingGlioblastoma | Glioblastoma Multiforme | Glioblastoma, IDH-wildtype | Glioblastoma Multiforme, Adult | Glioblastoma Multiforme of BrainUnited States, Belgium, Switzerland, Germany, Netherlands
-
Jasper GerritsenMassachusetts General Hospital; Universitaire Ziekenhuizen KU Leuven; University... and other collaboratorsRecruitingGlioblastoma | Glioblastoma Multiforme | Recurrent Glioblastoma | Glioblastoma, IDH-wildtype | Glioblastoma Multiforme, Adult | Glioblastoma Multiforme of Brain | Astrocytoma of Brain | Astrocytoma, MalignantUnited States, Germany, Netherlands, Switzerland, Belgium
-
Leland MethenyNational Cancer Institute (NCI)RecruitingGlioblastoma Multiforme | Supratentorial Gliosarcoma | Glioblastoma Multiforme, Adult | Supratentorial GlioblastomaUnited States
-
Northwestern UniversityAgenus Inc.; CarTheraRecruitingGlioblastoma Multiforme | Gliosarcoma | Newly Diagnosed Glioblastoma | Glioblastoma, Isocitric Dehydrogenase (IDH)-WildtypeUnited States
-
University Hospital, GenevaActive, not recruitingGlioblastoma Multiforme | Glioblastoma Multiforme of Brain | Glioma of Brain | Glioblastoma, AdultSwitzerland
-
Milton S. Hershey Medical CenterRecruitingGlioblastoma | Glioblastoma Multiforme | Glioblastoma Multiforme, Adult | Glioblastoma Multiforme of BrainUnited States
-
Northwestern UniversityNational Cancer Institute (NCI)RecruitingGlioblastoma | Astrocytoma | Recurrent Glioblastoma | MGMT-Unmethylated Glioblastoma | Glioblastoma, IDH-WildtypeUnited States
-
Milton S. Hershey Medical CenterNational Cancer Institute (NCI)RecruitingGlioblastoma | Glioblastoma Multiforme | Glioblastoma Multiforme, Adult | Glioblastoma Multiforme of BrainUnited States
Clinical Trials on Defactinib
-
Verastem, Inc.CompletedLung Cancer | Non Small Cell Lung CancerUnited States
-
Verastem, Inc.Completed
-
Memorial Sloan Kettering Cancer CenterVerastem, Inc.Recruiting
-
Verastem, Inc.TerminatedMalignant Pleural MesotheliomaUnited States
-
Verastem, Inc.CompletedNon Hematologic CancersJapan
-
University of UtahVerastem, Inc.Recruiting
-
University of OklahomaVerastem, Inc.RecruitingCervical Cancer | Solid Tumor | Endometrioid Cancer | Mucinous Ovarian Cancer | High Grade Serous Ovarian CancerUnited States
-
Memorial Sloan Kettering Cancer CenterVerastem, Inc.RecruitingMesonephric Gynecologic CancerUnited States
-
Verastem, Inc.TerminatedMalignant Pleural MesotheliomaUnited States, Belgium, United Kingdom, Sweden, Italy, Netherlands, France, Japan, Australia, Canada, New Zealand, Norway, Poland, South Africa, Spain
-
National Cancer Institute (NCI)Active, not recruitingHematopoietic and Lymphoid Cell Neoplasm | Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple MyelomaUnited States